Payment overview · 2025
General Payments
$439.91
19 reported records · 8 companies
Healthcare provider profile · identity verified
Luis Barba, MD
Allopathic & Osteopathic Physicians|General Practice · ORANGE CITY, FL · NPI 1992178750
Verified facts
What the public records show
CMS Open Payments records show Luis Barba, MD received $439.91 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.62 | 38.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.35 | 16.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.90 | 14.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.41 | 10.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.75 | 6.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $24.10 | 5.5% | 1 | 2025 |
| PhotoniCare Inc | Unresolved — no canonical attribution shown | $21.53 | 4.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.25 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.91 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $167.62 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.43 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.35 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.41 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.29 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| OtoSight Middle Ear Scope Normalized: otosight middle ear scope |
Device | PhotoniCare Inc | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 660 | 213 |
| Lisinopril | Lisinopril | 367 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 109 |
| Gabapentin | Gabapentin | 269 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 89 |
| Metformin Hcl | Metformin Hcl | 258 | 91 |
| Losartan Potassium | Losartan Potassium | 248 | 79 |
| Omeprazole | Omeprazole | 244 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 74 |
| Alendronate Sodium | Alendronate Sodium | 223 | 82 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 63 |
| Meloxicam | Meloxicam | 170 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 51 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 133 | 43 |
| Simvastatin | Simvastatin | 132 | 45 |
| Furosemide | Furosemide | 130 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 64 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 41 |
| Prednisone | Prednisone | 111 | 73 |
| Famotidine | Famotidine | 110 | 43 |
| Carvedilol | Carvedilol | 99 | 33 |
| Glipizide | Glipizide | 96 | 32 |
| Eliquis | Apixaban | 94 | 19 |
| Trazodone Hcl | Trazodone Hcl | 86 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 22 |
| Finasteride | Finasteride | 84 | 24 |
| Alprazolam | Alprazolam | 79 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 68 |
| Azithromycin | Azithromycin | 73 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 20 |
| Ibuprofen | Ibuprofen | 70 | 31 |
| Naproxen | Naproxen | 68 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 33 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 63 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 28 |
| Sertraline Hcl | Sertraline Hcl | 62 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | 33 |
| Tramadol Hcl | Tramadol Hcl | 60 | 18 |
| Ezetimibe | Ezetimibe | 59 | 22 |
| Glimepiride | Glimepiride | 59 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 19 |
| Allopurinol | Allopurinol | 51 | 17 |
| Montelukast Sodium | Montelukast Sodium | 51 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 50 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 35 |
| Buspirone Hcl | Buspirone Hcl | 43 | 11 |
| Pregabalin | Pregabalin | 41 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 22 |
| Farxiga | Dapagliflozin Propanediol | 39 | 13 |
| Clonidine Hcl | Clonidine Hcl | 38 | 16 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Donepezil Hcl | Donepezil Hcl | 35 | 12 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 13 |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Atenolol | Atenolol | 34 | 12 |
| Benazepril Hcl | Benazepril Hcl | 33 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 15 |
| Enalapril Maleate | Enalapril Maleate | 31 | 12 |
| Jardiance | Empagliflozin | 31 | 12 |
| Nystatin | Nystatin | 31 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 11 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 13 |
| Topiramate | Topiramate | 29 | 11 |
| Ketoconazole | Ketoconazole | 28 | 13 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | 14 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 25 | 16 |
| Baclofen | Baclofen | 24 | 11 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Potassium Chloride | Potassium Chloride | 23 | 11 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 14 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Benzonatate | Benzonatate | 15 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Temazepam | Temazepam | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.91 · 19 records | ABBVIE INC. | AIRSUPRA, FARXIGA, JARDIANCE, OtoSight Middle Ear Scope, Ozempic, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Vest Therapy Und | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error